IEP-01 is a unique anticancer immunotherapeutics developed by INEXOPLAT, which contains innate immune cell activators and cytokines targeting immune cells. When injected into the body, IEP-01 activates dendritic cells in the tumor microenvironment, thereby promoting the function of T cells.
Consequently, by stimulating immune cells such as dendritic cells, T cells, macrophages, and natural killer cells in the tumor microenvironment, IEP-01 induces death of cancer cells, exhibiting excellent anticancer effects.
Unlike conventional immunotherapeutics, which have had limitations in their effectiveness against solid tumors with suppressed immune responses, IEP-01 is a next-generation anticancer immunotherapeutics with a novel therapeutic mechanism based on changes in the tumor microenvironment, thus expanding its applicability to various cancer types, including solid tumors.